Literature DB >> 22632127

Short communication: factors influencing time to CD4(+) T cell counts >200 cells/mm(3) in HIV-infected individuals with CD4(+) T cell <50 cells/mm(3) at the time of starting combination antiretroviral therapy.

Nam Su Ku1, Young Goo Song, Sang Hoon Han, Sun Bean Kim, Hye-won Kim, Su Jin Jeong, Chang Oh Kim, June Myung Kim, Jun Yong Choi.   

Abstract

We evaluated factors influencing time to CD4(+) T cell counts >200 cells/mm(3) in HIV-infected individuals with CD4(+) T cell <50 cells/mm(3) starting combination antiretroviral therapy (cART). We included a total of 29 patients on successful cART for more than 1 year. In a logistic regression model, higher pre-cART CD4(+) T cell counts were significantly associated with shorter time to CD4(+) T cell counts >200cells/mm(3) in HIV-infected individuals with baseline CD4(+) T cell <50 cells/mm(3). In survival analysis, patients having higher pre-cART CD4(+) T cell counts, especially 40-49 cells/mm(3), were at significantly higher risk of achieving CD4(+) T cell counts >200 cells/mm(3).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22632127      PMCID: PMC3505051          DOI: 10.1089/AID.2011.0282

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  18 in total

1.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Authors:  R S Hogg; B Yip; K J Chan; E Wood; K J Craib; M V O'Shaughnessy; J S Montaner
Journal:  JAMA       Date:  2001-11-28       Impact factor: 56.272

2.  When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.

Authors:  A Cozzi Lepri; A N Phillips; A d'Arminio Monforte; F Castelli; A Antinori; A de Luca; P Pezzotti; F Alberici; A Cargnel; P Grima; R Piscopo; T Prestileo; G Scalise; M Vigevani; M Moroni
Journal:  AIDS       Date:  2001-05-25       Impact factor: 4.177

3.  Missed opportunities for earlier diagnosis of HIV infection--South Carolina, 1997-2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-12-01       Impact factor: 17.586

Review 4.  Tuberculosis and HIV disease: two decades of a dual epidemic.

Authors:  Muktar H Aliyu; Hamisu M Salihu
Journal:  Wien Klin Wochenschr       Date:  2003-10-31       Impact factor: 1.704

5.  Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America.

Authors:  Judith A Aberg; Jonathan E Kaplan; Howard Libman; Patricia Emmanuel; Jean R Anderson; Valerie E Stone; James M Oleske; Judith S Currier; Joel E Gallant
Journal:  Clin Infect Dis       Date:  2009-09-01       Impact factor: 9.079

Review 6.  CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review.

Authors:  D S Stein; J A Korvick; S H Vermund
Journal:  J Infect Dis       Date:  1992-02       Impact factor: 5.226

7.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

8.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1992-12-18

9.  Epidemiological characteristics of HIV-infected women in the Republic of Korea: A low HIV prevalence country.

Authors:  Jin-Hee Lee; Eun-ju Lee; Sung Soon Kim; Jeong-Gu Nam; Jiyoung Whang; Mee-Kyung Kee
Journal:  J Public Health Policy       Date:  2009-09       Impact factor: 2.222

10.  Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.

Authors:  Andrew M Abaasa; Jim Todd; Kenneth Ekoru; Joan N Kalyango; Jonathan Levin; Emmanuel Odeke; Charles A S Karamagi
Journal:  BMC Health Serv Res       Date:  2008-11-20       Impact factor: 2.655

View more
  1 in total

1.  Add-on Pyridostigmine Enhances CD4+ T-Cell Recovery in HIV-1-Infected Immunological Non-Responders: A Proof-of-Concept Study.

Authors:  Sergio I Valdés-Ferrer; José C Crispín; Pablo F Belaunzarán-Zamudio; Carlos A Rodríguez-Osorio; Bernardo Cacho-Díaz; Jorge Alcocer-Varela; Carlos Cantú-Brito; Juan Sierra-Madero
Journal:  Front Immunol       Date:  2017-10-18       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.